Molecular Psychiatry
June 25, 2026
Clotilde Guidetti, Maurizio Fava, George I. Papakostas
Major depressive disorder (MDD) and treatment-resistant depression (TRD) are prevalent and debilitating conditions. Over 50% of patients have inadequate response to first-line serotonergic antidepressants and are left with suboptimal treatment options. Rapid-acting and individually tailored treatments for MDD remain major unmet needs. This review discusses promising rapid-acting treatments,...
International Journal of Innovative Technologies in Social Science
June 24, 2026
Aleksandra Łoś, Kacper Szkodziński, Inga Jakubczyk et al.
Introduction: Depressive disorders are one of the greatest public health challenges worldwide, affecting up to 16% of the population over a lifetime and significantly impacting quality of life, disability, and premature mortality. Major depressive disorder (MDD) is a leading cause of disability, despite the availability of numerous treatment options. In 20–50% of patients, traditional...
International Journal of Innovative Technologies in Social Science
June 24, 2026
Irmina Grygutis, Oskar Mikołajczyk, Kornelia Julia Fimiarz et al.
Background: Treatment-resistant depression (TRD) is associated with substantial functional impairment, suicide risk, and health-care costs. Ketamine and its S-enantiomer, esketamine, have emerged as rapid-acting glutamatergic treatment options for TRD. Aim: This review aims to synthesize current evidence on the different ketamine administration routes for TRD, with a focus on acute and...
European Psychiatry
June 23, 2026
Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Journal of Psychopharmacology
June 23, 2026
Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska et al.
BACKGROUND: Major depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of serotonergic psychedelics, such as...
medRxiv
June 23, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Henricus G. Ruhé et al.
preprint
Abstract Major depressive disorder (MDD) is a leading cause of disability worldwide with risk of onset and recurrence linked to depressive ruminative thought patterns. Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment for depression that targets the ability to recognise, decenter, and disengage from ruminative thought patterns. Elucidating how MBCT impacts hierarchical...
Frontiers in Psychology
June 22, 2026
Zhihua Zheng, Wei Xu, Jianhua Shen et al.
Background: Guided by Acceptance and Commitment Therapy (ACT), this study examined whether trait mindfulness and psychological inflexibility and experiential avoidance-related processes, assessed using the Acceptance and Action Questionnaire-II (AAQ-II), were statistically linked to the association between physical exercise and depressive symptoms among college students. Methods: A...
Journal of Education, Health and Sport
June 22, 2026
Urszula Szuleta, Wiktoria Zawada, Krystian Kaczmarek et al.
Introduction and purpose. Major depressive disorder is a serious clinical problem. Current treatments are often unsuccessful, and many patients do not achieve full remission. In a reanalysis of the STAR*D study, the cumulative remission rate after up to four treatment steps was about 41%, which highlights the limitations of currently available antidepressant strategies[1]. In recent years,...
INNOVAPATH
June 22, 2026
Muhammad Bilal Akram, Ali Sher, Areena Fatima et al.
Treatment-resistant depression (TRD) represents a major clinical and public health challenge, affecting a substantial proportion of patients with major depressive disorder who fail to achieve remission despite adequate pharmacotherapy. Emerging evidence suggests that TRD is a heterogeneous condition driven by complex interactions among neurobiological, inflammatory, and psychosocial factors....
UNC Libraries
June 21, 2026
Verina Guirguis
Esketamine is an effective rapid-acting pharmacological intervention for treatment-resistant depression. However, the temporal dynamics of underlying brain networks associated with the improvement of depressive symptoms remain elusive. This observational study seeks to delineate alteration in network activity within 90 minutes of nasal Esketamine administration, with a focus on exploring its...
Indian Journal of YOGA Exercise & Sport Science and Physical Education
June 20, 2026
Kusum Sharma, Dr. Abhishek Bhardwaj
Aim of the study: This comprehensive review aims to compile the corpus of research on the therapeutic effectiveness of yoga in enhancing the mental health and well-being of new mothers with symptoms of postpartum depression. The present study is an attempt to look at how yoga practice in the postnatal period after delivery of the baby can help in reducing the symptoms of postpartum depression...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
June 20, 2026
Jen-Ping Chen, Chih-Wei Hsu, Yi-Ya Fang et al.
Although esketamine shows efficacy for treatment-resistant depression, its potential effectiveness in cancer-related depression (CRD) has not been well-established. We therefore evaluated the real-world effectiveness and safety of esketamine in CRD using a target trial emulation framework based on anonymized electronic health records from the TriNetX network. Adults aged 18-74 years with CRD...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
June 20, 2026
Xin Ding, Kenji Hashimoto, Jian-Jun Yang
Major depressive disorder (MDD) is a leading cause of disability worldwide, and currently available antidepressants remain limited by delayed onset of action, incomplete response, and adverse effects. Ketamine is a rapid-acting antidepressant, whereas xanomeline, an M1/M4 muscarinic receptor agonist, may represent a mechanistically distinct non-monoaminergic strategy. However, the molecular...
Research Square
June 19, 2026
Aline Frick, Grace Blest‐hopley, Manesh Grin et al.
preprint
Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...
Annals of Medicine and Surgery
June 18, 2026
Astrit Sabani, Adnan Khatak
Treatment-resistant depression (TRD) remains a major clinical challenge and is typically defined as the persistence of depressive symptoms despite at least two adequate antidepressant trials. Individuals with TRD experience substantial morbidity, impaired functioning, and elevated suicide risk, highlighting the need for therapeutic strategies beyond incremental refinements of conventional...
Journal of Affective Disorders
June 17, 2026
Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin et al.
Stress worsens clinical outcomes in patients with major depressive disorder (MDD); however, timely accessible stress management tools remain limited. Digital interventions offer scalable adjunctive solutions early during pharmacological treatment. In this multicenter, assessor-blinded, randomized controlled crossover pilot trial, we conducted a preliminary evaluation of the short-term efficacy...
Social Science & Medicine
June 17, 2026
Shuang Lu, Renhui Lyu, Xiaolu Dai et al.
Rapid urbanization and unequal urban-rural development have driven large-scale internal migration in low- and middle-income countries, placing internal migrant children at increased risk for psychological distress and sociocultural marginalization. Although schools are critical settings for prevention, targeted interventions that support migrant students' psychological ("feeling well") and...
Journal of Medical Internet Research
June 17, 2026
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...
SSM - Mental Health
June 16, 2026
Caroline Krauser, Eduardo Jardim Simões, Chester Schmaltz et al.
Depressive and anxiety symptoms are one of the leading causes of years lived with disability worldwide. Mindfulness-based interventions (MBIs) have been shown to be one of the proven treatments for improving mild and moderate cases of depression and anxiety. However, there is still a gap regarding the feasibility and effectiveness of MBIs in the real world, especially in low- and middle-income...
European Psychiatry
June 16, 2026
A.H. Young, Lucie Bartova, N. Cardoner et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.